American Diabetes Association
Browse
DOCUMENT
Table_S1 (1).pdf (71.5 kB)
DOCUMENT
Supplemental_Figure_Legends.pdf (105.74 kB)
IMAGE
Figure_S1.tiff (1.12 MB)
IMAGE
Figure_S2.tiff (1.12 MB)
IMAGE
Figure_S3.tiff (1.12 MB)
1/0
5 files

ß-cell glucose sensitivity to assess changes in ß-cell function in recent onset stage 3 type 1 diabetes

figure
posted on 2023-06-27, 18:44 authored by Stephen E Gitelman, Carmella Evans-Molina, Annamaria Guolo, Andrea Mari, Ele Ferrannini

Following a diagnosis of type 1 diabetes, persisting C-peptide secretion leads to improved glycemic control and outcomes. Residual ß-cell function is often assessed with serial mixed meal tolerance tests, but these tests do not correlate well with clinical outcomes. Herein, we instead employ ß-cell glucose sensitivity (bGS) to assess changes in ß-cell function, incorporating insulin secretion for a given serum glucose into the assessment of ß-cell function. We evaluated changes in bGS in individuals enrolled in the placebo arm of ten type 1 diabetes trials performed at diabetes onset. We found that bGS showed a more rapid decline in children, as compared to adolescents and adults. Individuals in the top quartile of bGS baseline distribution had a slower rate in loss of glycemic control time over time. Notably, half of this group were children and adolescents. Finally, to identify predictors of glycemic control throughout follow-up, we ran multivariate Cox models, and found that incorporating bGS significantly improved the overall model. Taken together, these data suggest that bGS may be of great utility in predicting those more likely to have a more robust clinical remission, and may be of use in new onset clinical trials design and in evaluating response to therapies.  

Funding

This work was supported by NIH grant R21 DK119800-01A1 (to EF, SEG, and CE-M).

History

Usage metrics

    Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC